HK75889A - Parenteral formulation of nimodipin, process for its preparation and its therapeutical use - Google Patents

Parenteral formulation of nimodipin, process for its preparation and its therapeutical use

Info

Publication number
HK75889A
HK75889A HK758/89A HK75889A HK75889A HK 75889 A HK75889 A HK 75889A HK 758/89 A HK758/89 A HK 758/89A HK 75889 A HK75889 A HK 75889A HK 75889 A HK75889 A HK 75889A
Authority
HK
Hong Kong
Prior art keywords
weight
per cent
parts
nimodipine
ethanol
Prior art date
Application number
HK758/89A
Other languages
German (de)
English (en)
Inventor
Dieter Dr. Hoff
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of HK75889A publication Critical patent/HK75889A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Claims (4)

1 - Formulation parentérale contenant a) 0,02% en poids de Nimodipine dissoute pour 100 parties en poids d'un solvant consistant en
b) 17 à 20% en poids d'un polyéthylèneglycol ayant un poids mohéculaire moyen de 200, 400 et/ou 600, 20% en poids d'éthanol
environ 60% en poids d'eau,
de même qu'éventuellement de petites quantités d'auxiliaires et/ou additifs usuels.
2 - Formulation parentérale selon la revendication 1, caractérisée en ce que le solvant contient 17% en poids de polyéthylèneglycol ayant un poids moléculaire moyen de 400 et 20% en poids d'éthanol.
3 - Procédé de fabrication de formulations parentérales contenant 0,02 partie en poids de Nimodipine dissoute pour 100 parties d'un solvant consistant en 17-20% en poids de polyéthylèneglycol ayant un poids moléculaire moyen de 200, 400 et/ou 600, 20% en poids d'éthanol, environ 60% en poids d'eau, ainsi éventuellement que de faibles quantités d'auxiliaires ou additifs usuels, caractérisé en ce qu'on dissout 0,02 partie en poids de Nimodipine dans un solvant contenant 17-20 parties en poids d'un polyéthylèneglycol de poids moléculaire moyen 200, 400 et/ou 600 et 20 parties en poids d'éthanol, on ajoute éventuellement de petites quantités d'auxiliaires et/ou additifs usuels et complète ensuite avec de l'eau à 100 parties en poids.
4 - Procédé selon la revendication 3, caractérisé en ce qu'on utilise 0,02% en poids de Nimodipine, 17% en poids de polyéthylèneglycol ayant un poids mocéculaire moyen de 400 et 20% en poids d'éthanol.
HK758/89A 1983-05-06 1989-09-21 Parenteral formulation of nimodipin, process for its preparation and its therapeutical use HK75889A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833316510 DE3316510A1 (de) 1983-05-06 1983-05-06 Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen

Publications (1)

Publication Number Publication Date
HK75889A true HK75889A (en) 1989-09-29

Family

ID=6198265

Family Applications (1)

Application Number Title Priority Date Filing Date
HK758/89A HK75889A (en) 1983-05-06 1989-09-21 Parenteral formulation of nimodipin, process for its preparation and its therapeutical use

Country Status (19)

Country Link
US (1) US5114956A (fr)
EP (1) EP0126315B1 (fr)
JP (1) JPS59206305A (fr)
KR (1) KR920000306B1 (fr)
AT (1) ATE24835T1 (fr)
AU (1) AU562293B2 (fr)
BE (1) BE899564A (fr)
CA (1) CA1220424A (fr)
DE (2) DE3316510A1 (fr)
DK (1) DK164148C (fr)
ES (1) ES8505542A1 (fr)
FR (1) FR2545354B1 (fr)
GR (1) GR81609B (fr)
HK (1) HK75889A (fr)
IL (1) IL71744A (fr)
IT (1) IT1181804B (fr)
PT (1) PT78542B (fr)
SG (1) SG44489G (fr)
ZA (1) ZA843352B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60246313A (ja) * 1984-05-22 1985-12-06 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンの注射剤およびその製法
FR2585574B1 (fr) * 1985-07-31 1988-09-09 Corbiere Jerome Nouvelles compositions pharmaceutiques anti-glaucomateuses a base de 1,4-dihydropyridines et leur procede d'obtention
DE3544692A1 (de) * 1985-12-18 1987-06-19 Bayer Ag Dihydropyridinspray, verfahren zu seiner herstellung und seine pharmazeutische verwendung
AT387518B (de) * 1985-12-18 1989-02-10 Bayer Ag Verfahren zur herstellung von fluessigen spruehpraeparaten von dihydropyridinen
DE3702105A1 (de) * 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
CA2011063C (fr) * 1989-02-28 1999-07-06 Calum B. Macfarlane Compose pharmaceutique de nicardipine pour administration parenterale
RU1804845C (ru) * 1991-02-15 1993-03-30 Институт Органического Синтеза Латвийской Ан Ноотропное вещество
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
MX9703988A (es) * 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
DE10142416A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Verfahren zur Herstellung von Lösungen
DE10142417A1 (de) * 2001-08-31 2003-03-20 Molecular And Clinical Drug Re Arzneimittel
US8034762B2 (en) 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2007047406A2 (fr) * 2005-10-14 2007-04-26 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques liquides de nimodipine
CN101431985A (zh) * 2006-04-28 2009-05-13 巴斯夫欧洲公司 在含水介质中加溶疏水活性物质的方法
WO2011095449A1 (fr) 2010-02-05 2011-08-11 Basf Se Procédé de solubilisation de substances actives hydrophobes dans un milieu aqueux
US8728504B2 (en) 2010-02-05 2014-05-20 Basf Se Process for solubilizing hydrophobic active ingredients in aqueous medium
US9364433B2 (en) 2011-04-28 2016-06-14 Borje S. Andersson Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US10092553B2 (en) 2016-04-13 2018-10-09 Nortic Holdings Inc. Stable nimodipine parenteral formulation
BR112018070960A2 (pt) * 2016-04-13 2019-01-29 Nortic Holdings Inc. formulação parenteral de nimodipina estável
EP3755326A4 (fr) 2018-02-22 2021-11-03 Nortic Holdings Inc. Formulation parentérale stable de nimodipine
CN119300828A (zh) 2022-05-16 2025-01-10 美国阿卡斯蒂制药股份有限公司 尼莫地平肠胃外给药
CN117502433A (zh) * 2023-11-08 2024-02-06 中国科学院海洋研究所 一种水母刺丝囊存放保护剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US4154839A (en) * 1975-11-05 1979-05-15 Bayer Aktiengesellschaft 2,6-Dimethyl-3-carboxymethoxy-4-(2-nitrophenyl)-5-carbisobutoxy-1,4-dihydropyridine
DE2650013C3 (de) * 1976-10-30 1981-04-02 Bayer Ag, 5090 Leverkusen 1.4-Dihydro-2.6-dimethyl-4-(3-nitrophenyl)-3.5-pyridindicarbonsäureisopropyl-(2-propoxy-äthyl)-ester, Verfahren zu seiner Herstellung sowie ihn enthaltende Arzneimittel
DE2815578C2 (de) * 1978-04-11 1986-01-16 Bayer Ag, 5090 Leverkusen Neue pharmazeutische Verwendung von Nimodipin
DE2841667A1 (de) * 1978-09-25 1980-04-10 Bayer Ag Fluorhaltige 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Also Published As

Publication number Publication date
PT78542A (en) 1984-06-01
FR2545354B1 (fr) 1986-09-26
DK224184A (da) 1984-11-07
IT8448139A1 (it) 1985-11-04
AU562293B2 (en) 1987-06-04
IT1181804B (it) 1987-09-30
EP0126315B1 (fr) 1987-01-14
IL71744A (en) 1988-04-29
ES531995A0 (es) 1985-06-01
AU2758384A (en) 1984-11-08
US5114956A (en) 1992-05-19
DK224184D0 (da) 1984-05-04
IT8448139A0 (it) 1984-05-04
IL71744A0 (en) 1984-09-30
PT78542B (en) 1986-07-14
ZA843352B (en) 1984-12-24
JPS59206305A (ja) 1984-11-22
JPH0422888B2 (fr) 1992-04-20
CA1220424A (fr) 1987-04-14
FR2545354A1 (fr) 1984-11-09
KR840009031A (ko) 1984-12-24
EP0126315A1 (fr) 1984-11-28
ES8505542A1 (es) 1985-06-01
DE3316510A1 (de) 1984-11-08
DK164148C (da) 1992-10-26
DK164148B (da) 1992-05-18
SG44489G (en) 1989-11-17
ATE24835T1 (de) 1987-01-15
KR920000306B1 (ko) 1992-01-11
BE899564A (fr) 1984-11-05
DE3461988D1 (en) 1987-02-19
GR81609B (fr) 1984-12-11

Similar Documents

Publication Publication Date Title
HK75889A (en) Parenteral formulation of nimodipin, process for its preparation and its therapeutical use
DE69233169T2 (de) Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
DE68910138T2 (de) Fumagillin als angiostatisches Mittel.
LU84546A1 (de) Verwendung von peptiden als medikamente
BG65417B1 (bg) Приложение на еритропоетин или еритропоетинови производни за лечение на мозъчни исхемии
Petersen et al. Chronic pain treatment with intravenous lidocaine
EP0249873B1 (fr) Médicament thérapeutique pour les ulcères de la peau
Osborn et al. Single-dose oral phenytoin loading
EP0166183A2 (fr) Utilisation de dérivés d'hydroxyindoles pour l'obtention d'un médicament destiné à réduire la pression sanguine
US3852453A (en) Method of enhancing vincamine compositions
JPH03135918A (ja) 免疫賦活剤
US3906107A (en) Aminoalkyl sulfate esters with diuretic activity
US4829068A (en) Treatment of disorders of the gastro-intestinal tract
US4335128A (en) Process for the treatment of patients suffering from drepanocytosis
DE69422496T2 (de) Mittel gegen malaria
DE68912159T2 (de) Dioxoquinazolinderivat enthaltendes Antihypertensivum.
US3764675A (en) Method of treatment of cardiac bradyarrhythmias
DE3626868A1 (de) Parenterale loesung
US3961064A (en) Pharmaceutical composition for remedy of hyperammoniemia
EP4603081A1 (fr) Composition injectable de brivaracétam
EP0273253A2 (fr) L'emploi de 6-allyl-2-amino-5,6,7,8-tétrahydro-4H-thiazolo-[5,4d]azépine pour la libération de l'hormone somatotrope
DE68905178T2 (de) Stabile waessrige zubereitung von aktivem vitamin-d-3.
KR19990022036A (ko) 방사선 장해의 치료방법
US4393054A (en) Method of treating cardiac arrhythmia
DE2201350A1 (de) Aufhebung der immunsuppressiven wirkung von corticoiden

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20040423

PE Patent expired